Therefore, in order to investigate whether long term treatment with GLP-1 was feasible at all, GLP-1 was given as a continuous subcutaneous infusion for 6 weeks in a trial in obese people with severe Type 2 diabetes (98). Here, GCG is linked to type 2 diabetes mellitus.